Trial Profile
A Phase II Trial of DCTD-Sponsored Dasatinib in Recurrent/Persistent Ovary, Fallopian Tube, Primary Peritoneal, and Endometrial Clear Cell Carcinoma Characterized for the Retention or Loss of BAF250a Expression
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 02 Aug 2023
Price :
$35
*
At a glance
- Drugs Dasatinib (Primary)
- Indications Carcinoma; Endometrial cancer; Fallopian tube cancer; Ovarian cancer; Peritoneal cancer; Uterine cancer
- Focus Therapeutic Use
- 13 Jul 2023 Status changed from active, no longer recruiting to discontinued.
- 20 Mar 2017 Status changed from suspended to active, no longer recruiting.
- 11 Aug 2016 Status changed from recruiting to suspended for assessment.